Cabaletta Bio (CABA) Projected to Post Earnings on Wednesday

Cabaletta Bio (NASDAQ:CABA - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.67) per share for the quarter.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.04). On average, analysts expect Cabaletta Bio to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cabaletta Bio Stock Performance

NASDAQ CABA traded down $0.11 during mid-day trading on Monday, reaching $1.92. 2,375,207 shares of the stock were exchanged, compared to its average volume of 1,544,940. The business's 50 day moving average is $1.37 and its 200-day moving average is $2.19. Cabaletta Bio has a 1 year low of $0.99 and a 1 year high of $13.50. The company has a market capitalization of $97.43 million, a P/E ratio of -0.89 and a beta of 2.72.

Institutional Investors Weigh In On Cabaletta Bio

Hedge funds have recently modified their holdings of the business. Comerica Bank raised its position in shares of Cabaletta Bio by 2,292.1% in the first quarter. Comerica Bank now owns 41,599 shares of the company's stock valued at $58,000 after buying an additional 39,860 shares during the last quarter. Invesco Ltd. increased its position in Cabaletta Bio by 357.1% during the first quarter. Invesco Ltd. now owns 61,675 shares of the company's stock worth $85,000 after purchasing an additional 48,181 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new position in Cabaletta Bio during the first quarter worth about $102,000.

Analyst Upgrades and Downgrades

CABA has been the topic of a number of recent analyst reports. Morgan Stanley lowered their price target on shares of Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating on the stock in a report on Tuesday, April 1st. HC Wainwright reaffirmed a "buy" rating and set a $25.00 price objective on shares of Cabaletta Bio in a report on Tuesday, April 1st. Wells Fargo & Company decreased their price objective on shares of Cabaletta Bio from $6.00 to $3.00 and set an "equal weight" rating on the stock in a report on Tuesday, April 1st. Guggenheim increased their price objective on shares of Cabaletta Bio from $23.00 to $25.00 and gave the company a "buy" rating in a report on Thursday. Finally, UBS Group decreased their price objective on shares of Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $20.33.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.